Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Distributes electricity

Amgen Boulder, Inc., a subsidiary of Amgen, Inc., is a company headquartered in Longmont, CO. The firm discovers, develops, and produces protein-based human pharmaceuticals.

Biopelle, Inc. manufactures cosmetics. The firm develops a unique product portfolio to improve the health and appearance of the skin. The company was founded in August 2005 and is headquartered in Ferndale, MI.

New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Molecular Probes provides fluorescence-based detection products and solutions for biomedical and other scientific research worldwide. Its product portfolio includes approximately 3000 fluorescent probes and biochemicals for research use in cell biology, molecular biology, proteomics, immunology, biochemistry, and the neurosciences.

Life Technologies Corporation operates as a biotechnology tools company. The company's systems, consumables and services enable researchers to accelerate scientific exploration, to discoveries and developments. Life Technologies was created by the combination of [Invitrogen Corporation](/organization/invitrogen) and [Applied Biosystems, Inc.](/organization/applied-biosystems) in November of 2008, and Life Technologies continues to serve its customers under those two well-known brands. Invitrogen is the premier provider of reagents and consumables that are usable across multiple platforms, while Applied Biosystems remains the top provider of systems-based, end-to-end solutions in areas such as PCR, genetic sequencing, and mass spectrometry. The company delivers a range of products and services, including systems, instruments, reagents, and custom services. Its portfolio of products includes technologies for capillary electrophoresis based sequencing, sequencing, mass spectrometry, sample preparation, cell culture, RNA interference analysis, functional genomics research, proteomics and cell biology applications, as well as clinical diagnostic applications and water testing analysis.

Provides diagnostic and therapeutic services for urological disorders

Cistron Biotechnology, Inc. manufactures and sells cytokine products. The company was founded by Henry Grause and is headquartered in Pine Brook, NJ.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world.

Hainan Zhengkang Pharmaceutical Co., Ltd., established on 1999-01-06, The scope of business includes the operation of pre-packaged food,Healthy food,special nutritional food,Liquor business,rice wine,wine,cosmetic,Seal powder,Wolfberry,ginseng,yam,Epimedium,Cinnamon,Eucommia,Dendrobium candidum extract,American Ginseng Extract,Tea polyphenols,lotus leaf extract,Alisma Extract,Jiaogulan Extract,maca powder,Cornus officinalis extract,Morinda Citrifolia Extract,Ganoderma Extract,Cordyceps militaris,Hardware building materials,auto parts,Sales of computers and computer software.(General operating items self-management,Licensed business projects are operated on the basis of relevant licenses or approval documents)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Rockfield Technology (Dalian) Co., Ltd., established on 2022-04-22, Business scope includes general items:Engineering and Technology Research and Experimental Development,Domestic trade agent,Import and export agency,Technology Import and Export,Import and export,Food import and export,Import and export commodity inspection and appraisal,Information Technology Consulting Services,sales agent,Healthy food(prepackaged)Sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

AFFiRiS AG develops and produces vaccines for therapeutic treatment of chronic diseases. It provides research services and develops vaccines based on peptide antigens applied in the fields of biochemistry, molecular and cell biology, immunology and veterinary medicine. AFFiRiS was founded by Walter Schmidt and Frank Mattner in November 2003 and is headquartered in Vienna, Austria.

Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.

Qingdao Chenlan Marine Biological Engineering Co., Ltd., established on 2015-12-09, Business scope includes licensed projects:Technology Import and Export;Import and export;Production of Class II Medical Devices;Class III medical device business;Production of Class III Medical Devices;pharmaceutical production;Drug retail;Drug Wholesale;Cosmetic production;Production of hygiene products and single-use medical products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices;Land use right lease;New material technology research and development;Cosmetics Wholesale;Cosmetics Retail;Information Consulting Service(Not including licensing information consulting services);Sales of hygiene products and single-use medical products;New material technology promotion service.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)